NantHealth, Inc.

NH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NH stands at 0. In comparison, VEEV has a market cap of 47.5B. Regarding current trading prices, NH is priced at $1.35, while VEEV trades at $290.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NH currently has a P/E ratio of -0.12, whereas VEEV's P/E ratio is 61.77. In terms of profitability, NH's ROE is +0.35%, compared to VEEV's ROE of +0.14%. Regarding short-term risk, NH is more volatile compared to VEEV. This indicates potentially higher risk in terms of short-term price fluctuations for NH.Check VEEV's competition here

NH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NH stands at 0. In comparison, GEHC has a market cap of 34.3B. Regarding current trading prices, NH is priced at $1.35, while GEHC trades at $75.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NH currently has a P/E ratio of -0.12, whereas GEHC's P/E ratio is 15.41. In terms of profitability, NH's ROE is +0.35%, compared to GEHC's ROE of +0.25%. Regarding short-term risk, NH is more volatile compared to GEHC. This indicates potentially higher risk in terms of short-term price fluctuations for NH.Check GEHC's competition here

NH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NH stands at 0. In comparison, GEHCV has a market cap of 25.5B. Regarding current trading prices, NH is priced at $1.35, while GEHCV trades at $56.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NH currently has a P/E ratio of -0.12, whereas GEHCV's P/E ratio is N/A. In terms of profitability, NH's ROE is +0.35%, compared to GEHCV's ROE of +0.23%. Regarding short-term risk, NH is more volatile compared to GEHCV. This indicates potentially higher risk in terms of short-term price fluctuations for NH.Check GEHCV's competition here

NH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NH stands at 0. In comparison, DOCS has a market cap of 12.7B. Regarding current trading prices, NH is priced at $1.35, while DOCS trades at $67.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NH currently has a P/E ratio of -0.12, whereas DOCS's P/E ratio is 57.91. In terms of profitability, NH's ROE is +0.35%, compared to DOCS's ROE of +0.23%. Regarding short-term risk, NH is more volatile compared to DOCS. This indicates potentially higher risk in terms of short-term price fluctuations for NH.Check DOCS's competition here

NH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NH stands at 0. In comparison, SGFY has a market cap of 8.9B. Regarding current trading prices, NH is priced at $1.35, while SGFY trades at $30.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NH currently has a P/E ratio of -0.12, whereas SGFY's P/E ratio is 70.91. In terms of profitability, NH's ROE is +0.35%, compared to SGFY's ROE of -0.15%. Regarding short-term risk, NH is more volatile compared to SGFY. This indicates potentially higher risk in terms of short-term price fluctuations for NH.Check SGFY's competition here

NH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NH stands at 0. In comparison, HQY has a market cap of 7.8B. Regarding current trading prices, NH is priced at $1.35, while HQY trades at $89.82.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NH currently has a P/E ratio of -0.12, whereas HQY's P/E ratio is 65.56. In terms of profitability, NH's ROE is +0.35%, compared to HQY's ROE of +0.06%. Regarding short-term risk, NH is more volatile compared to HQY. This indicates potentially higher risk in terms of short-term price fluctuations for NH.Check HQY's competition here

NH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NH stands at 0. In comparison, RCM has a market cap of 6B. Regarding current trading prices, NH is priced at $1.35, while RCM trades at $14.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NH currently has a P/E ratio of -0.12, whereas RCM's P/E ratio is -102.21. In terms of profitability, NH's ROE is +0.35%, compared to RCM's ROE of -0.02%. Regarding short-term risk, NH is more volatile compared to RCM. This indicates potentially higher risk in terms of short-term price fluctuations for NH.Check RCM's competition here

NH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NH stands at 0. In comparison, BTSG has a market cap of 4.4B. Regarding current trading prices, NH is priced at $1.35, while BTSG trades at $24.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NH currently has a P/E ratio of -0.12, whereas BTSG's P/E ratio is 99.48. In terms of profitability, NH's ROE is +0.35%, compared to BTSG's ROE of +0.04%. Regarding short-term risk, NH is more volatile compared to BTSG. This indicates potentially higher risk in terms of short-term price fluctuations for NH.Check BTSG's competition here

NH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NH stands at 0. In comparison, BTSGU has a market cap of 4.2B. Regarding current trading prices, NH is priced at $1.35, while BTSGU trades at $86.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NH currently has a P/E ratio of -0.12, whereas BTSGU's P/E ratio is N/A. In terms of profitability, NH's ROE is +0.35%, compared to BTSGU's ROE of +0.04%. Regarding short-term risk, NH is more volatile compared to BTSGU. This indicates potentially higher risk in terms of short-term price fluctuations for NH.Check BTSGU's competition here

NH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NH stands at 0. In comparison, WGS has a market cap of 3.7B. Regarding current trading prices, NH is priced at $1.35, while WGS trades at $128.67.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NH currently has a P/E ratio of -0.12, whereas WGS's P/E ratio is 1608.31. In terms of profitability, NH's ROE is +0.35%, compared to WGS's ROE of +0.01%. Regarding short-term risk, NH is more volatile compared to WGS. This indicates potentially higher risk in terms of short-term price fluctuations for NH.Check WGS's competition here

NH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NH stands at 0. In comparison, ONEM has a market cap of 3.4B. Regarding current trading prices, NH is priced at $1.35, while ONEM trades at $16.47.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NH currently has a P/E ratio of -0.12, whereas ONEM's P/E ratio is -7.77. In terms of profitability, NH's ROE is +0.35%, compared to ONEM's ROE of -0.24%. Regarding short-term risk, NH is more volatile compared to ONEM. This indicates potentially higher risk in terms of short-term price fluctuations for NH.Check ONEM's competition here

NH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NH stands at 0. In comparison, PRVA has a market cap of 2.7B. Regarding current trading prices, NH is priced at $1.35, while PRVA trades at $21.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NH currently has a P/E ratio of -0.12, whereas PRVA's P/E ratio is 199.91. In terms of profitability, NH's ROE is +0.35%, compared to PRVA's ROE of +0.02%. Regarding short-term risk, NH is more volatile compared to PRVA. This indicates potentially higher risk in terms of short-term price fluctuations for NH.Check PRVA's competition here

NH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NH stands at 0. In comparison, PINC has a market cap of 2.1B. Regarding current trading prices, NH is priced at $1.35, while PINC trades at $25.14.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NH currently has a P/E ratio of -0.12, whereas PINC's P/E ratio is 24.65. In terms of profitability, NH's ROE is +0.35%, compared to PINC's ROE of +0.01%. Regarding short-term risk, NH is more volatile compared to PINC. This indicates potentially higher risk in terms of short-term price fluctuations for NH.Check PINC's competition here

NH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NH stands at 0. In comparison, PGNY has a market cap of 2B. Regarding current trading prices, NH is priced at $1.35, while PGNY trades at $23.53.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NH currently has a P/E ratio of -0.12, whereas PGNY's P/E ratio is 39.88. In terms of profitability, NH's ROE is +0.35%, compared to PGNY's ROE of +0.12%. Regarding short-term risk, NH is more volatile compared to PGNY. This indicates potentially higher risk in terms of short-term price fluctuations for NH.Check PGNY's competition here

NH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NH stands at 0. In comparison, CERT has a market cap of 1.8B. Regarding current trading prices, NH is priced at $1.35, while CERT trades at $11.47.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NH currently has a P/E ratio of -0.12, whereas CERT's P/E ratio is 229.40. In terms of profitability, NH's ROE is +0.35%, compared to CERT's ROE of +0.01%. Regarding short-term risk, NH is more volatile compared to CERT. This indicates potentially higher risk in terms of short-term price fluctuations for NH.Check CERT's competition here

NH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NH stands at 0. In comparison, TXG has a market cap of 1.8B. Regarding current trading prices, NH is priced at $1.35, while TXG trades at $14.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NH currently has a P/E ratio of -0.12, whereas TXG's P/E ratio is -20.43. In terms of profitability, NH's ROE is +0.35%, compared to TXG's ROE of -0.12%. Regarding short-term risk, NH is more volatile compared to TXG. This indicates potentially higher risk in terms of short-term price fluctuations for NH.Check TXG's competition here

NH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NH stands at 0. In comparison, PHR has a market cap of 1.8B. Regarding current trading prices, NH is priced at $1.35, while PHR trades at $29.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NH currently has a P/E ratio of -0.12, whereas PHR's P/E ratio is -40.18. In terms of profitability, NH's ROE is +0.35%, compared to PHR's ROE of -0.16%. Regarding short-term risk, NH is more volatile compared to PHR. This indicates potentially higher risk in terms of short-term price fluctuations for NH.Check PHR's competition here

NH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NH stands at 0. In comparison, NXGN has a market cap of 1.6B. Regarding current trading prices, NH is priced at $1.35, while NXGN trades at $23.94.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NH currently has a P/E ratio of -0.12, whereas NXGN's P/E ratio is -266.00. In terms of profitability, NH's ROE is +0.35%, compared to NXGN's ROE of -0.01%. Regarding short-term risk, NH is more volatile compared to NXGN. This indicates potentially higher risk in terms of short-term price fluctuations for NH.Check NXGN's competition here

NH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NH stands at 0. In comparison, GDRX has a market cap of 1.6B. Regarding current trading prices, NH is priced at $1.35, while GDRX trades at $4.56.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NH currently has a P/E ratio of -0.12, whereas GDRX's P/E ratio is 50.67. In terms of profitability, NH's ROE is +0.35%, compared to GDRX's ROE of +0.08%. Regarding short-term risk, NH is more volatile compared to GDRX. This indicates potentially higher risk in terms of short-term price fluctuations for NH.Check GDRX's competition here

NH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NH stands at 0. In comparison, OMCL has a market cap of 1.5B. Regarding current trading prices, NH is priced at $1.35, while OMCL trades at $33.62.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NH currently has a P/E ratio of -0.12, whereas OMCL's P/E ratio is 67.24. In terms of profitability, NH's ROE is +0.35%, compared to OMCL's ROE of +0.02%. Regarding short-term risk, NH is more volatile compared to OMCL. This indicates potentially higher risk in terms of short-term price fluctuations for NH.Check OMCL's competition here

NH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NH stands at 0. In comparison, SDGR has a market cap of 1.5B. Regarding current trading prices, NH is priced at $1.35, while SDGR trades at $20.32.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NH currently has a P/E ratio of -0.12, whereas SDGR's P/E ratio is -8.19. In terms of profitability, NH's ROE is +0.35%, compared to SDGR's ROE of -0.46%. Regarding short-term risk, NH is more volatile compared to SDGR. This indicates potentially higher risk in terms of short-term price fluctuations for NH.Check SDGR's competition here

NH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NH stands at 0. In comparison, AGTI has a market cap of 1.4B. Regarding current trading prices, NH is priced at $1.35, while AGTI trades at $10.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NH currently has a P/E ratio of -0.12, whereas AGTI's P/E ratio is -71.79. In terms of profitability, NH's ROE is +0.35%, compared to AGTI's ROE of -0.02%. Regarding short-term risk, NH is more volatile compared to AGTI. This indicates potentially higher risk in terms of short-term price fluctuations for NH.Check AGTI's competition here

NH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NH stands at 0. In comparison, TDOC has a market cap of 1.4B. Regarding current trading prices, NH is priced at $1.35, while TDOC trades at $7.68.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NH currently has a P/E ratio of -0.12, whereas TDOC's P/E ratio is -6.67. In terms of profitability, NH's ROE is +0.35%, compared to TDOC's ROE of -0.14%. Regarding short-term risk, NH is more volatile compared to TDOC. This indicates potentially higher risk in terms of short-term price fluctuations for NH.Check TDOC's competition here

NH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NH stands at 0. In comparison, CTEV has a market cap of 1.2B. Regarding current trading prices, NH is priced at $1.35, while CTEV trades at $72.16.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NH currently has a P/E ratio of -0.12, whereas CTEV's P/E ratio is -1.76. In terms of profitability, NH's ROE is +0.35%, compared to CTEV's ROE of -9.96%. Regarding short-term risk, NH is more volatile compared to CTEV. This indicates potentially higher risk in terms of short-term price fluctuations for NH.Check CTEV's competition here

NH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NH stands at 0. In comparison, EVH has a market cap of 1.1B. Regarding current trading prices, NH is priced at $1.35, while EVH trades at $9.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NH currently has a P/E ratio of -0.12, whereas EVH's P/E ratio is -5.99. In terms of profitability, NH's ROE is +0.35%, compared to EVH's ROE of -0.17%. Regarding short-term risk, NH is more volatile compared to EVH. This indicates potentially higher risk in terms of short-term price fluctuations for NH.Check EVH's competition here

NH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NH stands at 0. In comparison, HSTM has a market cap of 822.2M. Regarding current trading prices, NH is priced at $1.35, while HSTM trades at $27.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NH currently has a P/E ratio of -0.12, whereas HSTM's P/E ratio is 41.40. In terms of profitability, NH's ROE is +0.35%, compared to HSTM's ROE of +0.06%. Regarding short-term risk, NH is more volatile compared to HSTM. This indicates potentially higher risk in terms of short-term price fluctuations for NH.Check HSTM's competition here

NH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NH stands at 0. In comparison, MPLN-WT has a market cap of 625.2M. Regarding current trading prices, NH is priced at $1.35, while MPLN-WT trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NH currently has a P/E ratio of -0.12, whereas MPLN-WT's P/E ratio is N/A. In terms of profitability, NH's ROE is +0.35%, compared to MPLN-WT's ROE of -9.96%. Regarding short-term risk, NH is less volatile compared to MPLN-WT. This indicates potentially lower risk in terms of short-term price fluctuations for NH.Check MPLN-WT's competition here

NH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NH stands at 0. In comparison, ACCD has a market cap of 575.6M. Regarding current trading prices, NH is priced at $1.35, while ACCD trades at $7.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NH currently has a P/E ratio of -0.12, whereas ACCD's P/E ratio is -3.08. In terms of profitability, NH's ROE is +0.35%, compared to ACCD's ROE of -0.45%. Regarding short-term risk, NH is more volatile compared to ACCD. This indicates potentially higher risk in terms of short-term price fluctuations for NH.Check ACCD's competition here

NH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NH stands at 0. In comparison, SY has a market cap of 538.6M. Regarding current trading prices, NH is priced at $1.35, while SY trades at $4.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NH currently has a P/E ratio of -0.12, whereas SY's P/E ratio is -4.55. In terms of profitability, NH's ROE is +0.35%, compared to SY's ROE of -0.28%. Regarding short-term risk, NH is more volatile compared to SY. This indicates potentially higher risk in terms of short-term price fluctuations for NH.Check SY's competition here

NH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NH stands at 0. In comparison, SHCR has a market cap of 531.8M. Regarding current trading prices, NH is priced at $1.35, while SHCR trades at $1.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NH currently has a P/E ratio of -0.12, whereas SHCR's P/E ratio is -3.76. In terms of profitability, NH's ROE is +0.35%, compared to SHCR's ROE of -0.17%. Regarding short-term risk, NH is more volatile compared to SHCR. This indicates potentially higher risk in terms of short-term price fluctuations for NH.Check SHCR's competition here

NH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NH stands at 0. In comparison, NUTX has a market cap of 513.3M. Regarding current trading prices, NH is priced at $1.35, while NUTX trades at $92.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NH currently has a P/E ratio of -0.12, whereas NUTX's P/E ratio is 1.72. In terms of profitability, NH's ROE is +0.35%, compared to NUTX's ROE of +0.58%. Regarding short-term risk, NH is more volatile compared to NUTX. This indicates potentially higher risk in terms of short-term price fluctuations for NH.Check NUTX's competition here

NH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NH stands at 0. In comparison, DH has a market cap of 422.6M. Regarding current trading prices, NH is priced at $1.35, while DH trades at $4.06.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NH currently has a P/E ratio of -0.12, whereas DH's P/E ratio is -1.51. In terms of profitability, NH's ROE is +0.35%, compared to DH's ROE of -0.72%. Regarding short-term risk, NH is more volatile compared to DH. This indicates potentially higher risk in terms of short-term price fluctuations for NH.Check DH's competition here

NH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NH stands at 0. In comparison, SLGCW has a market cap of 396.2M. Regarding current trading prices, NH is priced at $1.35, while SLGCW trades at $0.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NH currently has a P/E ratio of -0.12, whereas SLGCW's P/E ratio is -0.16. In terms of profitability, NH's ROE is +0.35%, compared to SLGCW's ROE of -0.19%. Regarding short-term risk, NH is more volatile compared to SLGCW. This indicates potentially higher risk in terms of short-term price fluctuations for NH.Check SLGCW's competition here

NH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NH stands at 0. In comparison, SLGC has a market cap of 396.2M. Regarding current trading prices, NH is priced at $1.35, while SLGC trades at $2.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NH currently has a P/E ratio of -0.12, whereas SLGC's P/E ratio is -3.04. In terms of profitability, NH's ROE is +0.35%, compared to SLGC's ROE of -0.19%. Regarding short-term risk, NH is more volatile compared to SLGC. This indicates potentially higher risk in terms of short-term price fluctuations for NH.Check SLGC's competition here

NH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NH stands at 0. In comparison, MPLN has a market cap of 375M. Regarding current trading prices, NH is priced at $1.35, while MPLN trades at $23.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NH currently has a P/E ratio of -0.12, whereas MPLN's P/E ratio is -0.23. In terms of profitability, NH's ROE is +0.35%, compared to MPLN's ROE of -9.96%. Regarding short-term risk, NH is more volatile compared to MPLN. This indicates potentially higher risk in terms of short-term price fluctuations for NH.Check MPLN's competition here

NH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NH stands at 0. In comparison, SPOK has a market cap of 368.8M. Regarding current trading prices, NH is priced at $1.35, while SPOK trades at $17.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NH currently has a P/E ratio of -0.12, whereas SPOK's P/E ratio is 21.58. In terms of profitability, NH's ROE is +0.35%, compared to SPOK's ROE of +0.15%. Regarding short-term risk, NH is more volatile compared to SPOK. This indicates potentially higher risk in terms of short-term price fluctuations for NH.Check SPOK's competition here

NH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NH stands at 0. In comparison, NRC has a market cap of 354.5M. Regarding current trading prices, NH is priced at $1.35, while NRC trades at $15.37.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NH currently has a P/E ratio of -0.12, whereas NRC's P/E ratio is 19.96. In terms of profitability, NH's ROE is +0.35%, compared to NRC's ROE of +0.61%. Regarding short-term risk, NH is more volatile compared to NRC. This indicates potentially higher risk in terms of short-term price fluctuations for NH.Check NRC's competition here

NH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NH stands at 0. In comparison, OPRX has a market cap of 320.2M. Regarding current trading prices, NH is priced at $1.35, while OPRX trades at $17.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NH currently has a P/E ratio of -0.12, whereas OPRX's P/E ratio is -31.94. In terms of profitability, NH's ROE is +0.35%, compared to OPRX's ROE of -0.08%. Regarding short-term risk, NH is more volatile compared to OPRX. This indicates potentially higher risk in terms of short-term price fluctuations for NH.Check OPRX's competition here

NH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NH stands at 0. In comparison, TBRG has a market cap of 307.4M. Regarding current trading prices, NH is priced at $1.35, while TBRG trades at $20.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NH currently has a P/E ratio of -0.12, whereas TBRG's P/E ratio is -26.95. In terms of profitability, NH's ROE is +0.35%, compared to TBRG's ROE of -0.07%. Regarding short-term risk, NH is more volatile compared to TBRG. This indicates potentially higher risk in terms of short-term price fluctuations for NH.Check TBRG's competition here

NH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NH stands at 0. In comparison, SLP has a market cap of 293.3M. Regarding current trading prices, NH is priced at $1.35, while SLP trades at $14.57.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NH currently has a P/E ratio of -0.12, whereas SLP's P/E ratio is -4.63. In terms of profitability, NH's ROE is +0.35%, compared to SLP's ROE of -0.37%. Regarding short-term risk, NH is more volatile compared to SLP. This indicates potentially higher risk in terms of short-term price fluctuations for NH.Check SLP's competition here

NH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NH stands at 0. In comparison, TRHC has a market cap of 284M. Regarding current trading prices, NH is priced at $1.35, while TRHC trades at $10.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NH currently has a P/E ratio of -0.12, whereas TRHC's P/E ratio is -4.27. In terms of profitability, NH's ROE is +0.35%, compared to TRHC's ROE of +121.31%. Regarding short-term risk, NH is more volatile compared to TRHC. This indicates potentially higher risk in terms of short-term price fluctuations for NH.Check TRHC's competition here

NH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NH stands at 0. In comparison, SMFR has a market cap of 246.4M. Regarding current trading prices, NH is priced at $1.35, while SMFR trades at $0.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NH currently has a P/E ratio of -0.12, whereas SMFR's P/E ratio is N/A. In terms of profitability, NH's ROE is +0.35%, compared to SMFR's ROE of +0.13%. Regarding short-term risk, NH is more volatile compared to SMFR. This indicates potentially higher risk in terms of short-term price fluctuations for NH.Check SMFR's competition here

NH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NH stands at 0. In comparison, SOPH has a market cap of 241.2M. Regarding current trading prices, NH is priced at $1.35, while SOPH trades at $3.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NH currently has a P/E ratio of -0.12, whereas SOPH's P/E ratio is -3.28. In terms of profitability, NH's ROE is +0.35%, compared to SOPH's ROE of -0.79%. Regarding short-term risk, NH is more volatile compared to SOPH. This indicates potentially higher risk in terms of short-term price fluctuations for NH.Check SOPH's competition here

NH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NH stands at 0. In comparison, HCAT has a market cap of 230.8M. Regarding current trading prices, NH is priced at $1.35, while HCAT trades at $3.28.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NH currently has a P/E ratio of -0.12, whereas HCAT's P/E ratio is -2.17. In terms of profitability, NH's ROE is +0.35%, compared to HCAT's ROE of -0.28%. Regarding short-term risk, NH is more volatile compared to HCAT. This indicates potentially higher risk in terms of short-term price fluctuations for NH.Check HCAT's competition here

NH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NH stands at 0. In comparison, CPSI has a market cap of 133.7M. Regarding current trading prices, NH is priced at $1.35, while CPSI trades at $9.19.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NH currently has a P/E ratio of -0.12, whereas CPSI's P/E ratio is -183.80. In terms of profitability, NH's ROE is +0.35%, compared to CPSI's ROE of -0.14%. Regarding short-term risk, NH is more volatile compared to CPSI. This indicates potentially higher risk in terms of short-term price fluctuations for NH.Check CPSI's competition here

NH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NH stands at 0. In comparison, CCLD has a market cap of 119.8M. Regarding current trading prices, NH is priced at $1.35, while CCLD trades at $2.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NH currently has a P/E ratio of -0.12, whereas CCLD's P/E ratio is -141.50. In terms of profitability, NH's ROE is +0.35%, compared to CCLD's ROE of +0.22%. Regarding short-term risk, NH is more volatile compared to CCLD. This indicates potentially higher risk in terms of short-term price fluctuations for NH.Check CCLD's competition here

NH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NH stands at 0. In comparison, AUGX has a market cap of 115.9M. Regarding current trading prices, NH is priced at $1.35, while AUGX trades at $2.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NH currently has a P/E ratio of -0.12, whereas AUGX's P/E ratio is -4.99. In terms of profitability, NH's ROE is +0.35%, compared to AUGX's ROE of -1.06%. Regarding short-term risk, NH is more volatile compared to AUGX. This indicates potentially higher risk in terms of short-term price fluctuations for NH.Check AUGX's competition here

NH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NH stands at 0. In comparison, AMWL has a market cap of 115.8M. Regarding current trading prices, NH is priced at $1.35, while AMWL trades at $7.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NH currently has a P/E ratio of -0.12, whereas AMWL's P/E ratio is -0.89. In terms of profitability, NH's ROE is +0.35%, compared to AMWL's ROE of -0.41%. Regarding short-term risk, NH is more volatile compared to AMWL. This indicates potentially higher risk in terms of short-term price fluctuations for NH.Check AMWL's competition here

NH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NH stands at 0. In comparison, CCLDO has a market cap of 111M. Regarding current trading prices, NH is priced at $1.35, while CCLDO trades at $21.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NH currently has a P/E ratio of -0.12, whereas CCLDO's P/E ratio is N/A. In terms of profitability, NH's ROE is +0.35%, compared to CCLDO's ROE of +0.22%. Regarding short-term risk, NH is more volatile compared to CCLDO. This indicates potentially higher risk in terms of short-term price fluctuations for NH.Check CCLDO's competition here

NH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NH stands at 0. In comparison, EUDA has a market cap of 96.6M. Regarding current trading prices, NH is priced at $1.35, while EUDA trades at $2.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NH currently has a P/E ratio of -0.12, whereas EUDA's P/E ratio is -4.81. In terms of profitability, NH's ROE is +0.35%, compared to EUDA's ROE of +3.46%. Regarding short-term risk, NH is more volatile compared to EUDA. This indicates potentially higher risk in terms of short-term price fluctuations for NH.Check EUDA's competition here

NH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NH stands at 0. In comparison, CCLDP has a market cap of 59.9M. Regarding current trading prices, NH is priced at $1.35, while CCLDP trades at $19.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NH currently has a P/E ratio of -0.12, whereas CCLDP's P/E ratio is N/A. In terms of profitability, NH's ROE is +0.35%, compared to CCLDP's ROE of +0.22%. Regarding short-term risk, NH is more volatile compared to CCLDP. This indicates potentially higher risk in terms of short-term price fluctuations for NH.Check CCLDP's competition here

NH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NH stands at 0. In comparison, FORA has a market cap of 55.1M. Regarding current trading prices, NH is priced at $1.35, while FORA trades at $1.77.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NH currently has a P/E ratio of -0.12, whereas FORA's P/E ratio is -59.00. In terms of profitability, NH's ROE is +0.35%, compared to FORA's ROE of -0.02%. Regarding short-term risk, NH is more volatile compared to FORA. This indicates potentially higher risk in terms of short-term price fluctuations for NH.Check FORA's competition here

NH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NH stands at 0. In comparison, BEATW has a market cap of 44.4M. Regarding current trading prices, NH is priced at $1.35, while BEATW trades at $0.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NH currently has a P/E ratio of -0.12, whereas BEATW's P/E ratio is -0.60. In terms of profitability, NH's ROE is +0.35%, compared to BEATW's ROE of -4.48%. Regarding short-term risk, NH is more volatile compared to BEATW. This indicates potentially higher risk in terms of short-term price fluctuations for NH.Check BEATW's competition here

NH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NH stands at 0. In comparison, BEAT has a market cap of 37.7M. Regarding current trading prices, NH is priced at $1.35, while BEAT trades at $1.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NH currently has a P/E ratio of -0.12, whereas BEAT's P/E ratio is -1.59. In terms of profitability, NH's ROE is +0.35%, compared to BEAT's ROE of -4.48%. Regarding short-term risk, NH is more volatile compared to BEAT. This indicates potentially higher risk in terms of short-term price fluctuations for NH.Check BEAT's competition here

NH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NH stands at 0. In comparison, SNCE has a market cap of 34.7M. Regarding current trading prices, NH is priced at $1.35, while SNCE trades at $5.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NH currently has a P/E ratio of -0.12, whereas SNCE's P/E ratio is -0.27. In terms of profitability, NH's ROE is +0.35%, compared to SNCE's ROE of -0.47%. Regarding short-term risk, NH is more volatile compared to SNCE. This indicates potentially higher risk in terms of short-term price fluctuations for NH.Check SNCE's competition here

NH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NH stands at 0. In comparison, AKLI has a market cap of 34.1M. Regarding current trading prices, NH is priced at $1.35, while AKLI trades at $0.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NH currently has a P/E ratio of -0.12, whereas AKLI's P/E ratio is -0.71. In terms of profitability, NH's ROE is +0.35%, compared to AKLI's ROE of -0.70%. Regarding short-term risk, NH is more volatile compared to AKLI. This indicates potentially higher risk in terms of short-term price fluctuations for NH.Check AKLI's competition here

NH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NH stands at 0. In comparison, SHLT has a market cap of 33.6M. Regarding current trading prices, NH is priced at $1.35, while SHLT trades at $2.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NH currently has a P/E ratio of -0.12, whereas SHLT's P/E ratio is -3.87. In terms of profitability, NH's ROE is +0.35%, compared to SHLT's ROE of -0.07%. Regarding short-term risk, NH is more volatile compared to SHLT. This indicates potentially higher risk in terms of short-term price fluctuations for NH.Check SHLT's competition here

NH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NH stands at 0. In comparison, SHCRW has a market cap of 32.5M. Regarding current trading prices, NH is priced at $1.35, while SHCRW trades at $0.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NH currently has a P/E ratio of -0.12, whereas SHCRW's P/E ratio is -0.00. In terms of profitability, NH's ROE is +0.35%, compared to SHCRW's ROE of -0.17%. Regarding short-term risk, NH is more volatile compared to SHCRW. This indicates potentially higher risk in terms of short-term price fluctuations for NH.Check SHCRW's competition here

NH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NH stands at 0. In comparison, ONMD has a market cap of 25.6M. Regarding current trading prices, NH is priced at $1.35, while ONMD trades at $0.78.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NH currently has a P/E ratio of -0.12, whereas ONMD's P/E ratio is -7.80. In terms of profitability, NH's ROE is +0.35%, compared to ONMD's ROE of +0.26%. Regarding short-term risk, NH is more volatile compared to ONMD. This indicates potentially higher risk in terms of short-term price fluctuations for NH.Check ONMD's competition here

NH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NH stands at 0. In comparison, STRM has a market cap of 23.2M. Regarding current trading prices, NH is priced at $1.35, while STRM trades at $5.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NH currently has a P/E ratio of -0.12, whereas STRM's P/E ratio is -2.40. In terms of profitability, NH's ROE is +0.35%, compared to STRM's ROE of -0.68%. Regarding short-term risk, NH is more volatile compared to STRM. This indicates potentially higher risk in terms of short-term price fluctuations for NH.Check STRM's competition here

NH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NH stands at 0. In comparison, RNLX has a market cap of 22.5M. Regarding current trading prices, NH is priced at $1.35, while RNLX trades at $0.21.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NH currently has a P/E ratio of -0.12, whereas RNLX's P/E ratio is -0.33. In terms of profitability, NH's ROE is +0.35%, compared to RNLX's ROE of +1.94%. Regarding short-term risk, NH is more volatile compared to RNLX. This indicates potentially higher risk in terms of short-term price fluctuations for NH.Check RNLX's competition here

NH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NH stands at 0. In comparison, LIFW has a market cap of 22.4M. Regarding current trading prices, NH is priced at $1.35, while LIFW trades at $3.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NH currently has a P/E ratio of -0.12, whereas LIFW's P/E ratio is -0.02. In terms of profitability, NH's ROE is +0.35%, compared to LIFW's ROE of -17.49%. Regarding short-term risk, NH is more volatile compared to LIFW. This indicates potentially higher risk in terms of short-term price fluctuations for NH.Check LIFW's competition here

NH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NH stands at 0. In comparison, MGRX has a market cap of 18.2M. Regarding current trading prices, NH is priced at $1.35, while MGRX trades at $1.73.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NH currently has a P/E ratio of -0.12, whereas MGRX's P/E ratio is -0.49. In terms of profitability, NH's ROE is +0.35%, compared to MGRX's ROE of -0.85%. Regarding short-term risk, NH is more volatile compared to MGRX. This indicates potentially higher risk in terms of short-term price fluctuations for NH.Check MGRX's competition here

NH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NH stands at 0. In comparison, SCNX has a market cap of 16.6M. Regarding current trading prices, NH is priced at $1.35, while SCNX trades at $1.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NH currently has a P/E ratio of -0.12, whereas SCNX's P/E ratio is 2.02. In terms of profitability, NH's ROE is +0.35%, compared to SCNX's ROE of -0.25%. Regarding short-term risk, NH is more volatile compared to SCNX. This indicates potentially higher risk in terms of short-term price fluctuations for NH.Check SCNX's competition here

NH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NH stands at 0. In comparison, HCTI has a market cap of 16.6M. Regarding current trading prices, NH is priced at $1.35, while HCTI trades at $2.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NH currently has a P/E ratio of -0.12, whereas HCTI's P/E ratio is -0.03. In terms of profitability, NH's ROE is +0.35%, compared to HCTI's ROE of -1.91%. Regarding short-term risk, NH is more volatile compared to HCTI. This indicates potentially higher risk in terms of short-term price fluctuations for NH.Check HCTI's competition here

NH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NH stands at 0. In comparison, BBLN has a market cap of 14.1M. Regarding current trading prices, NH is priced at $1.35, while BBLN trades at $0.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NH currently has a P/E ratio of -0.12, whereas BBLN's P/E ratio is -0.04. In terms of profitability, NH's ROE is +0.35%, compared to BBLN's ROE of +4.89%. Regarding short-term risk, NH is more volatile compared to BBLN. This indicates potentially higher risk in terms of short-term price fluctuations for NH.Check BBLN's competition here

NH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NH stands at 0. In comparison, VSEEW has a market cap of 14.1M. Regarding current trading prices, NH is priced at $1.35, while VSEEW trades at $0.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NH currently has a P/E ratio of -0.12, whereas VSEEW's P/E ratio is N/A. In terms of profitability, NH's ROE is +0.35%, compared to VSEEW's ROE of -3.34%. Regarding short-term risk, NH is more volatile compared to VSEEW. This indicates potentially higher risk in terms of short-term price fluctuations for NH.Check VSEEW's competition here

NH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NH stands at 0. In comparison, VSEE has a market cap of 13M. Regarding current trading prices, NH is priced at $1.35, while VSEE trades at $0.82.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NH currently has a P/E ratio of -0.12, whereas VSEE's P/E ratio is -11.86. In terms of profitability, NH's ROE is +0.35%, compared to VSEE's ROE of -3.34%. Regarding short-term risk, NH is more volatile compared to VSEE. This indicates potentially higher risk in terms of short-term price fluctuations for NH.Check VSEE's competition here

NH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NH stands at 0. In comparison, INOV has a market cap of 12.9M. Regarding current trading prices, NH is priced at $1.35, while INOV trades at $33.06.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NH currently has a P/E ratio of -0.12, whereas INOV's P/E ratio is 17.87. In terms of profitability, NH's ROE is +0.35%, compared to INOV's ROE of +0.03%. Regarding short-term risk, NH is more volatile compared to INOV. This indicates potentially higher risk in terms of short-term price fluctuations for NH.Check INOV's competition here

NH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NH stands at 0. In comparison, BFRG has a market cap of 12.8M. Regarding current trading prices, NH is priced at $1.35, while BFRG trades at $1.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NH currently has a P/E ratio of -0.12, whereas BFRG's P/E ratio is -1.69. In terms of profitability, NH's ROE is +0.35%, compared to BFRG's ROE of -1.95%. Regarding short-term risk, NH is more volatile compared to BFRG. This indicates potentially higher risk in terms of short-term price fluctuations for NH.Check BFRG's competition here

NH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NH stands at 0. In comparison, ETAO has a market cap of 9.8M. Regarding current trading prices, NH is priced at $1.35, while ETAO trades at $1.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NH currently has a P/E ratio of -0.12, whereas ETAO's P/E ratio is -0.01. In terms of profitability, NH's ROE is +0.35%, compared to ETAO's ROE of -13.69%. Regarding short-term risk, NH is more volatile compared to ETAO. This indicates potentially higher risk in terms of short-term price fluctuations for NH.Check ETAO's competition here

NH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NH stands at 0. In comparison, HLTH has a market cap of 6.9M. Regarding current trading prices, NH is priced at $1.35, while HLTH trades at $0.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NH currently has a P/E ratio of -0.12, whereas HLTH's P/E ratio is -0.02. In terms of profitability, NH's ROE is +0.35%, compared to HLTH's ROE of -0.90%. Regarding short-term risk, NH is more volatile compared to HLTH. This indicates potentially higher risk in terms of short-term price fluctuations for NH.Check HLTH's competition here

NH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NH stands at 0. In comparison, UPH has a market cap of 5.3M. Regarding current trading prices, NH is priced at $1.35, while UPH trades at $0.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NH currently has a P/E ratio of -0.12, whereas UPH's P/E ratio is -0.07. In terms of profitability, NH's ROE is +0.35%, compared to UPH's ROE of -1.05%. Regarding short-term risk, NH is more volatile compared to UPH. This indicates potentially higher risk in terms of short-term price fluctuations for NH.Check UPH's competition here

NH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NH stands at 0. In comparison, BFRGW has a market cap of 5.2M. Regarding current trading prices, NH is priced at $1.35, while BFRGW trades at $1.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NH currently has a P/E ratio of -0.12, whereas BFRGW's P/E ratio is N/A. In terms of profitability, NH's ROE is +0.35%, compared to BFRGW's ROE of -1.95%. Regarding short-term risk, NH is more volatile compared to BFRGW. This indicates potentially higher risk in terms of short-term price fluctuations for NH.Check BFRGW's competition here

NH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NH stands at 0. In comparison, MSPR has a market cap of 4.3M. Regarding current trading prices, NH is priced at $1.35, while MSPR trades at $0.44.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NH currently has a P/E ratio of -0.12, whereas MSPR's P/E ratio is N/A. In terms of profitability, NH's ROE is +0.35%, compared to MSPR's ROE of -17.49%. Regarding short-term risk, NH is more volatile compared to MSPR. This indicates potentially higher risk in terms of short-term price fluctuations for NH.Check MSPR's competition here

NH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NH stands at 0. In comparison, ACON has a market cap of 4.3M. Regarding current trading prices, NH is priced at $1.35, while ACON trades at $7.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NH currently has a P/E ratio of -0.12, whereas ACON's P/E ratio is -0.61. In terms of profitability, NH's ROE is +0.35%, compared to ACON's ROE of -0.84%. Regarding short-term risk, NH is more volatile compared to ACON. This indicates potentially higher risk in terms of short-term price fluctuations for NH.Check ACON's competition here

NH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NH stands at 0. In comparison, ZCMD has a market cap of 4.1M. Regarding current trading prices, NH is priced at $1.35, while ZCMD trades at $0.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NH currently has a P/E ratio of -0.12, whereas ZCMD's P/E ratio is -7.33. In terms of profitability, NH's ROE is +0.35%, compared to ZCMD's ROE of -0.03%. Regarding short-term risk, NH is more volatile compared to ZCMD. This indicates potentially higher risk in terms of short-term price fluctuations for NH.Check ZCMD's competition here

NH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NH stands at 0. In comparison, PEAR has a market cap of 4.1M. Regarding current trading prices, NH is priced at $1.35, while PEAR trades at $0.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NH currently has a P/E ratio of -0.12, whereas PEAR's P/E ratio is -0.08. In terms of profitability, NH's ROE is +0.35%, compared to PEAR's ROE of -0.39%. Regarding short-term risk, NH is more volatile compared to PEAR. This indicates potentially higher risk in terms of short-term price fluctuations for NH.Check PEAR's competition here

NH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NH stands at 0. In comparison, PEARW has a market cap of 4.1M. Regarding current trading prices, NH is priced at $1.35, while PEARW trades at $0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NH currently has a P/E ratio of -0.12, whereas PEARW's P/E ratio is -0.00. In terms of profitability, NH's ROE is +0.35%, compared to PEARW's ROE of -0.39%. Regarding short-term risk, NH is more volatile compared to PEARW. This indicates potentially higher risk in terms of short-term price fluctuations for NH.Check PEARW's competition here

NH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NH stands at 0. In comparison, EUDAW has a market cap of 3.4M. Regarding current trading prices, NH is priced at $1.35, while EUDAW trades at $0.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NH currently has a P/E ratio of -0.12, whereas EUDAW's P/E ratio is N/A. In terms of profitability, NH's ROE is +0.35%, compared to EUDAW's ROE of +3.46%. Regarding short-term risk, NH is more volatile compared to EUDAW. This indicates potentially higher risk in terms of short-term price fluctuations for NH.Check EUDAW's competition here

NH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NH stands at 0. In comparison, WGSWW has a market cap of 2.6M. Regarding current trading prices, NH is priced at $1.35, while WGSWW trades at $0.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NH currently has a P/E ratio of -0.12, whereas WGSWW's P/E ratio is N/A. In terms of profitability, NH's ROE is +0.35%, compared to WGSWW's ROE of +0.01%. Regarding short-term risk, NH is more volatile compared to WGSWW. This indicates potentially higher risk in terms of short-term price fluctuations for NH.Check WGSWW's competition here

NH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NH stands at 0. In comparison, OTRK has a market cap of 2.3M. Regarding current trading prices, NH is priced at $1.35, while OTRK trades at $0.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NH currently has a P/E ratio of -0.12, whereas OTRK's P/E ratio is -0.02. In terms of profitability, NH's ROE is +0.35%, compared to OTRK's ROE of -2.70%. Regarding short-term risk, NH is more volatile compared to OTRK. This indicates potentially higher risk in terms of short-term price fluctuations for NH.Check OTRK's competition here

NH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NH stands at 0. In comparison, CMAX has a market cap of 1.6M. Regarding current trading prices, NH is priced at $1.35, while CMAX trades at $0.42.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NH currently has a P/E ratio of -0.12, whereas CMAX's P/E ratio is -0.00. In terms of profitability, NH's ROE is +0.35%, compared to CMAX's ROE of +3.36%. Regarding short-term risk, NH is more volatile compared to CMAX. This indicates potentially higher risk in terms of short-term price fluctuations for NH.Check CMAX's competition here

NH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NH stands at 0. In comparison, LIFWZ has a market cap of 1.3M. Regarding current trading prices, NH is priced at $1.35, while LIFWZ trades at $0.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NH currently has a P/E ratio of -0.12, whereas LIFWZ's P/E ratio is N/A. In terms of profitability, NH's ROE is +0.35%, compared to LIFWZ's ROE of -17.49%. Regarding short-term risk, NH is more volatile compared to LIFWZ. This indicates potentially higher risk in terms of short-term price fluctuations for NH.Check LIFWZ's competition here

NH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NH stands at 0. In comparison, WORX has a market cap of 1.2M. Regarding current trading prices, NH is priced at $1.35, while WORX trades at $0.32.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NH currently has a P/E ratio of -0.12, whereas WORX's P/E ratio is -0.28. In terms of profitability, NH's ROE is +0.35%, compared to WORX's ROE of -0.60%. Regarding short-term risk, NH is more volatile compared to WORX. This indicates potentially higher risk in terms of short-term price fluctuations for NH.Check WORX's competition here

NH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NH stands at 0. In comparison, FOXO has a market cap of 302.9K. Regarding current trading prices, NH is priced at $1.35, while FOXO trades at $0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NH currently has a P/E ratio of -0.12, whereas FOXO's P/E ratio is N/A. In terms of profitability, NH's ROE is +0.35%, compared to FOXO's ROE of -0.01%. Regarding short-term risk, NH is less volatile compared to FOXO. This indicates potentially lower risk in terms of short-term price fluctuations for NH.Check FOXO's competition here

NH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NH stands at 0. In comparison, KERN has a market cap of 162.3K. Regarding current trading prices, NH is priced at $1.35, while KERN trades at $0.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NH currently has a P/E ratio of -0.12, whereas KERN's P/E ratio is -0.01. In terms of profitability, NH's ROE is +0.35%, compared to KERN's ROE of -2.22%. Regarding short-term risk, NH is more volatile compared to KERN. This indicates potentially higher risk in terms of short-term price fluctuations for NH.Check KERN's competition here

NH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NH stands at 0. In comparison, KERNW has a market cap of 162.3K. Regarding current trading prices, NH is priced at $1.35, while KERNW trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NH currently has a P/E ratio of -0.12, whereas KERNW's P/E ratio is -0.00. In terms of profitability, NH's ROE is +0.35%, compared to KERNW's ROE of -2.22%. Regarding short-term risk, NH is less volatile compared to KERNW. This indicates potentially lower risk in terms of short-term price fluctuations for NH.Check KERNW's competition here

NH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NH stands at 0. In comparison, OTRKP has a market cap of 100.1K. Regarding current trading prices, NH is priced at $1.35, while OTRKP trades at $0.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NH currently has a P/E ratio of -0.12, whereas OTRKP's P/E ratio is -0.01. In terms of profitability, NH's ROE is +0.35%, compared to OTRKP's ROE of -2.70%. Regarding short-term risk, NH is more volatile compared to OTRKP. This indicates potentially higher risk in terms of short-term price fluctuations for NH.Check OTRKP's competition here

NH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NH stands at 0. In comparison, ICCT has a market cap of 97.5K. Regarding current trading prices, NH is priced at $1.35, while ICCT trades at $0.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NH currently has a P/E ratio of -0.12, whereas ICCT's P/E ratio is N/A. In terms of profitability, NH's ROE is +0.35%, compared to ICCT's ROE of +20.01%. Regarding short-term risk, NH is more volatile compared to ICCT. This indicates potentially higher risk in terms of short-term price fluctuations for NH.Check ICCT's competition here

NH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NH stands at 0. In comparison, LIFWW has a market cap of 60.1K. Regarding current trading prices, NH is priced at $1.35, while LIFWW trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NH currently has a P/E ratio of -0.12, whereas LIFWW's P/E ratio is N/A. In terms of profitability, NH's ROE is +0.35%, compared to LIFWW's ROE of -17.49%. Regarding short-term risk, NH is more volatile compared to LIFWW. This indicates potentially higher risk in terms of short-term price fluctuations for NH.Check LIFWW's competition here

NH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NH stands at 0. In comparison, MSPRZ has a market cap of 53.2K. Regarding current trading prices, NH is priced at $1.35, while MSPRZ trades at $0.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NH currently has a P/E ratio of -0.12, whereas MSPRZ's P/E ratio is N/A. In terms of profitability, NH's ROE is +0.35%, compared to MSPRZ's ROE of -17.49%. Regarding short-term risk, NH is more volatile compared to MSPRZ. This indicates potentially higher risk in terms of short-term price fluctuations for NH.Check MSPRZ's competition here

NH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NH stands at 0. In comparison, CMAXW has a market cap of 36.4K. Regarding current trading prices, NH is priced at $1.35, while CMAXW trades at $0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NH currently has a P/E ratio of -0.12, whereas CMAXW's P/E ratio is N/A. In terms of profitability, NH's ROE is +0.35%, compared to CMAXW's ROE of +3.36%. Regarding short-term risk, NH is more volatile compared to CMAXW. This indicates potentially higher risk in terms of short-term price fluctuations for NH.Check CMAXW's competition here

NH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NH stands at 0. In comparison, ACONW has a market cap of 26.3K. Regarding current trading prices, NH is priced at $1.35, while ACONW trades at $0.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NH currently has a P/E ratio of -0.12, whereas ACONW's P/E ratio is -0.01. In terms of profitability, NH's ROE is +0.35%, compared to ACONW's ROE of -0.84%. Regarding short-term risk, NH is more volatile compared to ACONW. This indicates potentially higher risk in terms of short-term price fluctuations for NH.Check ACONW's competition here

NH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NH stands at 0. In comparison, MSPRW has a market cap of 7K. Regarding current trading prices, NH is priced at $1.35, while MSPRW trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NH currently has a P/E ratio of -0.12, whereas MSPRW's P/E ratio is N/A. In terms of profitability, NH's ROE is +0.35%, compared to MSPRW's ROE of -17.49%. Regarding short-term risk, NH is more volatile compared to MSPRW. This indicates potentially higher risk in terms of short-term price fluctuations for NH.Check MSPRW's competition here

NH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NH stands at 0. In comparison, UTRS has a market cap of 89. Regarding current trading prices, NH is priced at $1.35, while UTRS trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NH currently has a P/E ratio of -0.12, whereas UTRS's P/E ratio is N/A. In terms of profitability, NH's ROE is +0.35%, compared to UTRS's ROE of -1.11%. Regarding short-term risk, NH is less volatile compared to UTRS. This indicates potentially lower risk in terms of short-term price fluctuations for NH.Check UTRS's competition here

NH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NH stands at 0. In comparison, MTBCO has a market cap of 0. Regarding current trading prices, NH is priced at $1.35, while MTBCO trades at $25.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NH currently has a P/E ratio of -0.12, whereas MTBCO's P/E ratio is N/A. In terms of profitability, NH's ROE is +0.35%, compared to MTBCO's ROE of +0.22%. Regarding short-term risk, NH is more volatile compared to MTBCO. This indicates potentially higher risk in terms of short-term price fluctuations for NH.Check MTBCO's competition here

NH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NH stands at 0. In comparison, CSLT has a market cap of 0. Regarding current trading prices, NH is priced at $1.35, while CSLT trades at $2.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NH currently has a P/E ratio of -0.12, whereas CSLT's P/E ratio is -37.27. In terms of profitability, NH's ROE is +0.35%, compared to CSLT's ROE of -0.42%. Regarding short-term risk, NH is more volatile compared to CSLT. This indicates potentially higher risk in terms of short-term price fluctuations for NH.Check CSLT's competition here

NH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NH stands at 0. In comparison, SMFRW has a market cap of 0. Regarding current trading prices, NH is priced at $1.35, while SMFRW trades at $0.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NH currently has a P/E ratio of -0.12, whereas SMFRW's P/E ratio is N/A. In terms of profitability, NH's ROE is +0.35%, compared to SMFRW's ROE of +0.01%. Regarding short-term risk, NH is more volatile compared to SMFRW. This indicates potentially higher risk in terms of short-term price fluctuations for NH.Check SMFRW's competition here